Real-World Prescribing Pattern of Asthma Management in China: A Retrospective, Descriptive Analysis
Abstract Background Asthma is a chronic inflammatory disorder of the airway that requires long-term medication management. Objective To describe the real-world prescribing patterns for asthma management in the Chinese population. Methods A retrospective analysis of 8,732 patients from January 2011 to September 2019 in 10 hospitals was conducted. Prescribing patterns of short-acting beta-agonists (SABA), long-acting beta-agonists (LABA), inhaled corticosteroids (ICS), intravenous corticosteroids, antihistamines, leukotriene receptor antagonists (LTRA), theophylline, antibiotics, and Chinese patent medicines were included in the analysis. Chi-square and logistic regression were calculated. P value of <0.05 was considered as statistical significance. Results ICS/LABA were prescribed for 2,940 (33.67%) patients with stable asthma and 141 (31.4%) patients with asthma exacerbations. LTRA was prescribed in 2,006 (22.97%) patients with stable asthma, and 86 (19.15%) patients with asthma exacerbations. Systemic antibiotics (46.1Z%), systemic corticosteroids (57.91%), and theophylline (51.45%) were frequently prescribed during exacerbations. A total of 5,766 patients (64.95%) were managed with traditional Chinese medication (TCM); 3237 patients (36.47%) received western medicine. Patients using ICS/LABA (P=0.019) and SABA (P=0.008) had a significantly lower rate of asthma exacerbations. Conclusions This study provides valuable insight into clinical practices of asthma management in China. Poor adherence to clinical reports was identified. Efforts are required to improve the quality of asthma care.